These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 24055835)

  • 21. In silico prediction of drug resistance due to S247R mutation of Influenza H1N1 neuraminidase protein.
    Mandal RS; Panda S; Das S
    J Biomol Struct Dyn; 2018 Mar; 36(4):966-980. PubMed ID: 28279127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.
    Pizzorno A; Bouhy X; Abed Y; Boivin G
    J Infect Dis; 2011 Jan; 203(1):25-31. PubMed ID: 21148493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme.
    Bantia S; Upshaw R; Babu YS
    Antiviral Res; 2011 Sep; 91(3):288-91. PubMed ID: 21722670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding mode analysis of anti-influenza drugs in H1N1 (2009) and H5N1 influenza A virus and designing of potential H1N1 inhibitors.
    Singh KhD; Kirubakaran P; Nagamani S; Karthikeyan M
    Int J Comput Biol Drug Des; 2015; 8(1):1-18. PubMed ID: 25869316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
    Hurt AC; Ernest J; Deng YM; Iannello P; Besselaar TG; Birch C; Buchy P; Chittaganpitch M; Chiu SC; Dwyer D; Guigon A; Harrower B; Kei IP; Kok T; Lin C; McPhie K; Mohd A; Olveda R; Panayotou T; Rawlinson W; Scott L; Smith D; D'Souza H; Komadina N; Shaw R; Kelso A; Barr IG
    Antiviral Res; 2009 Jul; 83(1):90-3. PubMed ID: 19501261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach.
    Karthick V; Shanthi V; Rajasekaran R; Ramanathan K
    Appl Biochem Biotechnol; 2012 May; 167(2):237-49. PubMed ID: 22544690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The inhibitory performance of flavonoid cyanidin-3-sambubiocide against H274Y mutation in H1N1 influenza virus.
    Kannan S; Kolandaivel P
    J Biomol Struct Dyn; 2018 Dec; 36(16):4255-4269. PubMed ID: 29199545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of zanamivir efficiency over the possible 2009 influenza A (H1N1) mutants by multiple molecular dynamics simulations and free energy calculations.
    Pan D; Sun H; Bai C; Shen Y; Jin N; Liu H; Yao X
    J Mol Model; 2011 Oct; 17(10):2465-73. PubMed ID: 21193941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)".
    Rungrotmongkol T; Malaisree M; Udommaneethanakit T; Hannongbua S
    Biophys Chem; 2009 Apr; 141(1):131-2; author reply 133. PubMed ID: 19231807
    [No Abstract]   [Full Text] [Related]  

  • 30. Neuraminidase inhibitor resistance in influenza viruses.
    Reece PA
    J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
    Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
    J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influenza virus resistance to neuraminidase inhibitors.
    Samson M; Pizzorno A; Abed Y; Boivin G
    Antiviral Res; 2013 May; 98(2):174-85. PubMed ID: 23523943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
    Ferraris O; Escuret V; Bouscambert-Duchamp M; Lina B; Morfin F
    Pathol Biol (Paris); 2010 Apr; 58(2):e69-78. PubMed ID: 20303677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.
    Tu V; Abed Y; Barbeau X; Carbonneau J; Fage C; Lagüe P; Boivin G
    Antiviral Res; 2017 Jan; 137():6-13. PubMed ID: 27838351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal.
    Barrett S; McKimm-Breschkin JL
    Antiviral Res; 2014 Aug; 108():30-5. PubMed ID: 24854981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase.
    Prachanronarong KL; Özen A; Thayer KM; Yilmaz LS; Zeldovich KB; Bolon DN; Kowalik TF; Jensen JD; Finberg RW; Wang JP; Kurt-Yilmaz N; Schiffer CA
    J Chem Theory Comput; 2016 Dec; 12(12):6098-6108. PubMed ID: 27951676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
    Neri-Bazán RM; García-Machorro J; Méndez-Luna D; Tolentino-López LE; Martínez-Ramos F; Padilla-Martínez II; Aguilar-Faisal L; Soriano-Ursúa MA; Trujillo-Ferrara JG; Fragoso-Vázquez MJ; Barrón BL; Correa-Basurto J
    Eur J Med Chem; 2017 Mar; 128():154-167. PubMed ID: 28182988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
    Oakley AJ; Barrett S; Peat TS; Newman J; Streltsov VA; Waddington L; Saito T; Tashiro M; McKimm-Breschkin JL
    J Med Chem; 2010 Sep; 53(17):6421-31. PubMed ID: 20695427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.
    McKimm-Breschkin JL; Rootes C; Mohr PG; Barrett S; Streltsov VA
    J Antimicrob Chemother; 2012 Aug; 67(8):1874-83. PubMed ID: 22563014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.